Evidence map›Paper›PMID 39221582›Full record

ArticleEuropean journal of translational myology2024

Intra-articular injections with Carboxymethyl-Chitosan in patients affected by knee osteoarthritis non-responders to hyaluronic acid: a pilot study.

Nicola Manocchio, Concetta Ljoka, Nicolò Piacentini, Roberto Sorge, Giulia Vita, Calogero Foti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of translational myology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicola ManocchioPhysical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata. nicola.manocchio@uniroma2.it.
Concetta LjokaPhysical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata, Italy; Physical and Rehabilitation Medicine Unit, Tor Vergata University Hospital, Rome. concetta.ljoka@ptvonline.it.
Nicolò PiacentiniPhysical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata. nicolo.piacentini@students.uniroma2.eu.
Roberto SorgeSystems Medicine, Biometric Unit, University of Rome Tor Vergata. sorge@uniroma2.it.
Giulia VitaPhysical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata. giulia.vita@students.uniroma2.eu.
Calogero FotiPhysical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata, Italy; Physical and Rehabilitation Medicine Unit, Tor Vergata University Hospital, Rome. foti@med.uniroma2.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) is a disabling disease that causes pain and functional limitation. OA symptoms can be treated with intra-articular injections of anti-inflammatory, viscosupplementary, or viscoinductive products. Non-responders to these approaches have limited options, often surgical (e.g. knee replacement). This retrospective study aims to evaluate the efficacy of a single injection of Carboxymethyl-Chitosan for advanced (Kellgren-Lawrence ≥3) and symptomatic knee OA in non-responders to hyaluronic acid. We enrolled 10 patients (5 female, 5 male). Treatment efficacy was assessed through the Visual Analogue Scale (VAS, pain) and the Knee Injury and Osteoarthritis Outcome Score (KOOS, knee function). Data are acquired from rating scales were administered at the time of injection (T0), one month (T1), three months (T2), and six months (T3) after treatment as for clinical practice. Results showed a significant improvement in pain and function at T1, with a subsequent gradual resumption of symptoms. In conclusion, the treatment showed a better outcome in the short term (i.e. up to 1 month after treatment); however, raw values of VAS and KOOS did not return to baseline levels showing a maintenance of improvement albeit not statistically significant.

Identifiers

PMID39221582
PMCPMC11487637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.